Advisory Committee Recommends Avastin, Herceptin Biosimilars

Clinical Trials Advisor
A A
An FDA advisory panel unanimously recommended that the agency approve two biosimilars for the cancer treatments Avastin (bevacizumab) and Herceptin (trastuzumab).

To View This Article:

Login

Subscribe To Clinical Trials Advisor